Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26065106 | 0.87 | HHAT (0.40) | HHATMEN1KMT2AGRIN2CGAA | |
| SCHEMBL26065091 | 0.78 | GRIN2C (0.41) | HHATMEN1KMT2AGRIN2CGAA | |
| SCHEMBL26065079 | 0.74 | GRIN2C (0.45) | HHATGRIN2CPOLBTP53 | |
| SCHEMBL26065094 | 0.74 | GRIN2C (0.45) | HHATGRIN2CTP53 | |
| SCHEMBL26065069 | 0.73 | GRIN2C (0.64) | GRIN2C | |
| SCHEMBL26065085 | 0.66 | HHAT (0.31) | HHAT | |
| SCHEMBL26065095 | 0.62 | TSHR (0.55) | HHATMEN1KMT2AGRIN2CPOLB | |
| SCHEMBL26065092 | 0.60 | HHAT (0.48) | HHATGRIN2CTP53 | |
| SCHEMBL26065070 | 0.60 | GRIN2C (0.62) | GRIN2C | |
| SCHEMBL28449155 | 0.57 | KMT2A (0.40) | HHATKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355593-A1 | N-methyl-D-aspartic Acid Receptor Modulators | UNIV EMORY (US) | 2023-11-09 | — | — | US | disclosed |
| US-11738008-B2 | N-methyl-D-aspartic acid receptor modulators | EMORY UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355593-A1 | N-methyl-D-aspartic Acid Receptor Modulators | GRIN1, GRIN2A, GRM1 | HHAT 944/4885MEN1 3916/4885KMT2A 839/4885 |
| US-11738008-B2 | N-methyl-D-aspartic acid receptor modulators | GRIN1, GRIN2A, GRM1 | HHAT 979/4885MEN1 3923/4885KMT2A 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.